GlassScriptPhysician profile
Adnan Majid
NPI 1790797561
$350,614.36
in general payments reported to CMS, 2019-2025
36 companies · $34K in 2025
The $34K reported for 2025 was more than what 97% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66K · 2020: $13K · 2021: $57K · 2022: $62K · 2023: $51K · 2024: $67K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $54K · Education: $48K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Travel and Lodging: $14K · Grant: $5,500 · Food and Beverage: $5,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $54,360.26 |
| Education | $48,400.59 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,792.50 |
| Travel and Lodging | $13,944.33 |
| Grant | $5,500.00 |
| Food and Beverage | $5,098.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Latin America, INC. | $99,715.75 | 2019-2025 | Eves Eus Ultrasound Bronchofibervideoscope, Evis Exera II Ultrasonic Bronchofibervideoscope, Evis Exera III Bronchovideoscope |
| Pinnacle Biologics, INC | $61,643.17 | 2019-2025 | Photofrin |
| Olympus Corporation of The Americas | $58,455.28 | 2019-2024 | Evis Exera III Bronchovideoscope, Eves Eus Ultrasound Bronchofibervideoscope |
| US Endoscopy | $20,800.00 | 2023-2025 | |
| Cook Incorporated | $20,464.11 | 2019-2025 | Blue Rhino |
| Boston Scientific Corporation | $19,941.03 | 2019-2025 | Ultraflex Esophageal Ng, General - Pulmonary, General - Therapies |
| Intuitive Surgical, INC. | $14,841.99 | 2019-2025 | Da Vinci Surgical System |
| Pulmonx Corporation | $13,881.87 | 2019-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Ethicon INC. | $12,488.22 | 2024-2025 | Monarch Platform |
| Olympus America INC. | $6,367.49 | 2019-2025 | Single-Use Flexible Video Bronchoscope, Spiration Valve System |
| Medtronic, INC. | $6,207.30 | 2021-2023 | Illumisite |
| Olympus Medical Systems Corporation | $5,538.36 | 2024 | |
| Spiration, INC. | $2,115.86 | 2019 | |
| Olympus Corporation | $1,463.17 | 2023-2024 | |
| Veran Medical Technologies, INC. | $1,408.22 | 2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gyrus Acmi, INC. | $1,333.45 | 2019-2024 | Spin Vision Video Processor |
| Steris Corporation | $895.35 | 2023-2025 | |
| Janssen Research & Development, LLC | $675.00 | 2025 | |
| Noah Medical Corporation | $532.08 | 2024 | Galaxy |
| Erbe USA INC | $521.44 | 2019-2025 | Vio3/Apc3/Erbecryo2, Erbe Cryo2, Vio3 Cryo Apc |
| Serpex Medical INC | $172.43 | 2025 | |
| Bard Peripheral Vascular, INC. | $171.13 | 2022 | |
| Covidien LP | $154.23 | 2019-2020 | |
| Philips North America LLC | $126.93 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $125.44 | 2023 | Breztri |
| Cook Medical LLC | $120.57 | 2021-2025 | Wayne |
| Takeda Pharmaceuticals U.S.A., INC. | $92.03 | 2020-2021 | |
| Verona Pharma, INC. | $82.10 | 2025 | Ohtuvayre |
| Rocket Medical LLC | $79.17 | 2022 | |
| Galvanize Therapeutics, INC | $71.87 | 2025 | Aliya System |
| Lumenis, INC | $59.34 | 2021 | |
| Pfizer INC. | $28.28 | 2023 | |
| Ambu INC. | $23.61 | 2022 | |
| Merck Sharp & Dohme LLC | $18.09 | 2024 | Keytruda |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adnan Majid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.